<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845374</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-H004</org_study_id>
    <nct_id>NCT03845374</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis</brief_title>
  <official_title>Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye-yon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye-yon Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, open-label, two arms, clinical study aim to evaluate
      the efficacy and safety of treatment with Hyper-CL™ lens + Antibiotics compared with
      treatment with Antibiotics only, in subjects with Bacterial keratitis.

      The design of the Hyper-CL™ lens increases contact time of the antibiotics on the cornea
      enabling increased bioavailability of the active drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Hyper-CL™ Therapeutic soft contact lenses for short-term wear (up to 7 days) are
      indicated for therapeutic use to promote corneal healing and relieve corneal pain by
      protecting the cornea during the treatment of acute or chronic pathologies, such as corneal
      edema, corneal erosions, entropion, bullous keratopathy, and corneal dystrophies as well as
      post-surgical conditions resulting from cataract extraction and corneal surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>40 patients will be randomized to one of the following 2 groups:
Treatment Group 1: Conventional treatment of topical Antibiotics+ Hyper-CL lens
Treatment Group 2: Conventional treatment with topical Antibiotics</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Bacterial keratitis severity score.</measure>
    <time_frame>From date of randomization up to 14 days</time_frame>
    <description>Will be measured by Bacterial keratitis severity score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bacterial Keratitis</condition>
  <arm_group>
    <arm_group_label>Conventional Antibiotics+ Hyper-CL™ lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment with topical Antibiotics+ Hyper-CL™ lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional treatment with topical Antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyper-CL™ lens</intervention_name>
    <description>Use of the Hyper-CL™</description>
    <arm_group_label>Conventional Antibiotics+ Hyper-CL™ lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 18-86 years old

          2. Subject with Bacterial keratitis in one eye only

        Exclusion Criteria:

          1. Sign of inflammation in both eyes

          2. Pregnancy

          3. Other active ocular infection

          4. Any infiltration suggesting other than bacterial infection e.g. parasite, fungal

          5. Any other condition which in the opinion of the investigator would place the patient
             at undue risk for participation.

          6. Participation in another clinical study within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lori Michaeli, MA</last_name>
    <phone>972722052400</phone>
    <email>lori@novatrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meital Abecassis</last_name>
      <phone>9724777-1130</phone>
      <email>m_abecassis@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rinat Rashty</last_name>
      <phone>97235302877</phone>
      <email>Rinat.Rashty@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

